End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 15 | Vericel Insider Sold Shares Worth $1,552,075, According to a Recent SEC Filing | MT |
Mar. 13 | Vericel Insider Sold Shares Worth $352,047, According to a Recent SEC Filing | MT |
Financials (USD)
Sales 2024 * | 239M | Sales 2025 * | 299M | Capitalization | 2.12B |
---|---|---|---|---|---|
Net income 2024 * | 4M | Net income 2025 * | 25M | EV / Sales 2024 * | 8.85 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.08 x |
P/E ratio 2024 * |
548
x | P/E ratio 2025 * |
90.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
Latest transcript on Aastrom Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 13-02-28 | |
Joseph Mara
DFI | Director of Finance/CFO | 49 | 21-01-24 |
Michael Halpin
COO | Chief Operating Officer | 62 | 17-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Wotton
BRD | Director/Board Member | 63 | 15-01-05 |
Kevin McLaughlin
BRD | Director/Board Member | 67 | 15-01-05 |
Robert Zerbe
CHM | Chairman | 73 | 06-01-15 |
1st Jan change | Capi. | |
---|---|---|
-5.99% | 84.46B | |
+3.95% | 40.85B | |
-26.37% | 27.69B | |
+50.57% | 24.28B | |
-6.59% | 17.09B | |
-32.37% | 13.67B | |
-10.45% | 11.79B | |
-15.88% | 11.86B | |
-4.19% | 8.07B |